| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $0.76B | +33.9% |
| Gross profit | $0.53B | — |
| Operating income | $0.12B | — |
| Net income | $0.09B | +157.3% |
| Gross margin | 69.5% | Net margin 12.0% |
| Segment | Revenue | Share |
|---|---|---|
| U.S.Omnipod | $0.52B | 67.7% |
| International Omnipod | $0.24B | 31.9% |
| Drug Delivery | $0.00B | 0.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $0.23B | 30.6% |
| R&D | $0.09B | 11.8% |
| SG&A | $0.32B | 41.6% |
| Tax & other | $0.03B | 4.1% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
INTC ・ IBKR ・ ICE ・ IFF ・ IP ・ INTU ・ ISRG ・ IVZ ・ INVH ・ IQV ・ IRM ・ JBHT
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies